

Inclusion Criteria:

- NICU infants ≥ 34 0/7 weeks GA at birth being treated with inhaled Nitric Oxide for PPHN
- Refer to PPHN guidelines for optimization of Respiratory Management

Exclusion Criteria:

- BPD
- CDH
- Pulmonary HTN team is consulted

FiO₂ weaning parameters:


Wean FiO₂ ~2-5% q 30 minutes for preductal sats >95% (or PaO₂>60mmHg)

SaO₂ ordered range:
92-97%

Weaning Failure Criteria:

Stop wean and return to the previous dose if any of the following occur:

- Preductal PaO₂ <50 or FiO₂ increases by >10
OR
- Pre/Post ductal saturation gradient >10



Inclusion & Exclusion Criteria

Inclusion Criteria

- NICU infants ≥ 34 0/7 weeks at birth being treated with inhaled Nitric Oxide for PPHN

Exclusion Criteria

- BPD
- CDH
- Premature infants < 34 weeks
- If Pulmonary HTN team is consulted

[iNO Algorithm](#)

Assessment & Monitoring

- Frequent Monitoring of Blood gases, preferably arterial
- Frequent calculation of OI with every blood gas
- Weaning FiO2 per parameters
- Ensure Cardiopulmonary optimization
- It is suggested that the lowest effective doses of iNO and O2 be used, to avoid excessive exposure to NO, Nitric dioxide (NO2), and methemoglobin (MetHb).
 - Check metHgb q 24 hours. If a patient is on iNO for 2 weeks, then the labs are spaced out to q.o.d
 - If metHgb > 5%, wean iNO if possible; if metHgb > 10%, treat with methylene blue, ascorbic acid after discussion with pharmacy.
- Nitric dioxide (NO2) alarm set NO2 alarm at 1 ppm.

[iNO Algorithm](#)

Treatments Not Recommended

- Doses greater than 20 ppm are not recommended
- Continuation of the pathway if additional vasodilator added
- Continuation of the pathway if no response as per the algorithm

[iNO Algorithm](#)

Risk Awareness & Zero Hero

Harmful impact on continuing iNO in the patient cohort that does not respond to iNO

[iNO Algorithm](#)

Key References

- Finer N, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. *Cochrane Database of Systematic Reviews*. Published online October 18, 2006. doi:10.1002/14651858.cd000399.pub2
- Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. *New England Journal of Medicine*. 2000;342(7):469-474. doi:10.1056/nejm200002173420704
- Spinale JM, Laskin BL, Sondheimer N, Swartz SJ, Goldstein SL. High-dose continuous renal replacement therapy for neonatal hyperammonemia. *Pediatric Nephrology*. 2013;28(6):983-986. doi:10.1007/s00467-013-2441-8
- Stenger MR. Hospital variation in nitric oxide use for premature infants. *Pediatrics*. 2012;129(4). doi:10.1542/peds.2011-1809d
- Davidson D, Barefield ES, Kattwinkel J, et al. Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn. *Pediatrics*. 1999;104(2):231-236. doi:10.1542/peds.104.2.231
- Fischer H, Singh T, Devlin L, et al. A quality improvement project improving the value of Ino utilization in preterm and term infants. *Journal of Perinatology*. 2020;41(1):164-172. doi:10.1038/s41372-020-0768-0
- Nelin LD, Potenziano JL. Inhaled nitric oxide for neonates with persistent pulmonary hypertension of the newborn in the CINRGI study: Time to treatment response. *BMC Pediatrics*. 2019;19(1). doi:10.1186/s12887-018-1368-4
- DiBlasi RM, Myers TR, Hess DR. Evidence-based clinical practice guideline: inhaled nitric oxide for neonates with acute hypoxic respiratory failure. *Respir Care*. 2010 Dec;55(12):1717-45. PMID: 21122181.
- Finer NN, Sun JW, Rich W, Knodel E, Barrington KJ. Randomized, prospective study of low-dose versus high-dose inhaled nitric oxide in the neonate with hypoxic respiratory failure. *Pediatrics*. 2001;108(4):949-955. doi:10.1542/peds.108.4.949
- Thomas CA, Valentine K. Utility of routine methemoglobin laboratory assays in critically ill pediatric subjects receiving inhaled nitric oxide. *Journal of Critical Care*. 2018;48:63-65. doi:10.1016/j.jcrc.2018.08.014
- Fei Q, Pan J, Zhang F, Lin Y, Yuan T. Comparison of Different Treatments of Persistent Pulmonary Hypertension of the Newborn: A Systematic Review and Network Meta-Analysis. *Crit Care Med*. 2024 Jun 1;52(6):e314-e322. doi: 10.1097/CCM.0000000000006227. Epub 2024 Feb 16. PMID: 38363176.
- Rhine WD, Suzuki S, Potenziano JL, Escalante S, Togari H. An Analysis of Time to Improvement in Oxygenation in Japanese Preterm and Late Preterm or Term Neonates With Hypoxic Respiratory Failure and Pulmonary Hypertension. *Clin Ther*. 2019 May;41(5):910-919. doi: 10.1016/j.clinthera.2019.03.008. Epub 2019 Apr 12. PMID: 30987776.

iNO Algorithm

Quality Measures & Clinical Support Tools

Goals

1. Wean iNO appropriately and in a timely manner
2. Limit excessive use of iNO
3. Discontinue iNO when no response

Potential Areas of Research

Incidence of late responders and non-responders

Quality Measures

Outcome Measure

iNO utilization in number of hours

Process Measures

Process Measure 1: Utilization of the order set amongst those eligible (Was the order set used Yes No)

Process Measure 2: For patients where FiO_2 remains $< 50\%$ for 30 hours,

1. Was the iNO wean started (defined as any decrease in iNO)?
2. Was iNO discontinued during that timeframe of 30 hours?

Balancing Measure

1. Number of patients where iNO was restarted within 24 hours of discontinuation.
2. Rate of Methemoglobin level $>10\%$ in any patient on iNO

[iNO Algorithm](#)

Clinical Support Tools

Epic Order Sets

- NICU Inhaled Nitric Oxide Clinical Pathway

[iNO Algorithm](#)

Pathway Team & Process

Pathway Development Team:

Leader(s):

Neonatology:

Roopali Bapat, MD, MSHQS
George El-Ferzli, MD

Members:

Neonatology:

Sarah Knouff, NNP
Ahmed Osman, MD
Shama Patel, MD, MPH

Neonatology Fellows:

Mary Crume
Allison Lure
Michael Ratti
Ashley Wethall

NICU Respiratory Care:

Erin Wishloff

Advanced Care Pharmacy:

Jackie Magers, PharmD

Nursing Education Specialist:

Debbie Dunn, RN

Clinical Pathways Program:

Medical Director – Neonatology:

Roopali Bapat, MD, MSHQS

Medical Director – Quality:

Ryan Bode, MD, MBOE

Medical Director – Clinical Informatics & Emergency Medicine:

Laura Rust, MD, MPH

Business & Development Manager:

Rekha Voruganti, MBOE, LSSBB

Program Coordinators:

Tahje Brown, MBA
Joaquin Serantes, BA

Clinical Pathway Approved

Medical Director – Associate Chief Quality Officer, Center for Clinical Excellence:

Ryan Bode, MD, MBOE

Advisory Committee Date: September, 2022

Origination Date: *September, 2022*

Next Revision Date: *September, 2025*

Clinical Pathway Development

This clinical pathway was developed using the process described in the NCH Clinical Pathway Development Manual Version 6, 2022. Clinical Pathways at Nationwide Children's Hospital (NCH) are standards which provide general guidance to clinicians. Patient choice, clinician judgment, and other relevant factors in diagnosing and treating patients remain central to the selection of diagnostic tests and therapy. The ordering provider assumes all risks associated with care decisions. NCH assumes no responsibility for any adverse consequences, errors, or omissions that may arise from the use or reliance on these guidelines. NCH's clinical pathways are reviewed periodically for consistency with new evidence; however, new developments may not be represented, and NCH makes no guarantees, representations, or warranties with respect to the information provided in this clinical pathway.

Copyright © 2023. Nationwide Children's Hospital. All rights reserved. No part of this document may be reproduced, displayed, modified, or distributed in any form without the express written permission of Nationwide Children's Hospital.

For more information about our pathways and program please contact:
ClinicalPathways@NationwideChildrens.org

iNO Algorithm